Corbus Pharmaceuticals focuses its therapeutic pipeline on severe, life-threatening illnesses within oncology and metabolic disorders. In oncology, its programs target Nectin-4-expressing solid tumors, including head and neck squamous cell carcinoma (such as oropharyngeal cancer) and cervical cancer. In metabolic health, the company targets obesity through novel peripherally restricted inverse agonist mechanisms designed to regulate metabolic pathways safely.